Stephan Bramow

Stephan Bramow

Auto-generated profile, based on publicly available information

Stephan Bramow

Department of Neurology, Danish Multiple Sclerosis Center, Copenhagen University Hospital, Rigshospitalet Glostrup, Glostrup, Denmark

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2009 in Brain
Verified
Journal Article
Open access
PDF file
JFJosa M Frischer
Josa M Frischer
SBStephan Bramow
Stephan Bramow
ADAssunta Dal-Bianco
Assunta Dal-Bianco
CLClaudia F. Lucchinetti
Claudia F. Lucchinetti
HRHelmut Rauschka
Helmut Rauschka
HLHans Lassmann
Hans Lassmann
Some recent studies suggest that in progressive multiple sclerosis, neurodegeneration may occur independently from inflammation. The aim of our study was to analyse the interdependence of inflammation, neurodegeneration and disease progression in various multiple sclerosis stages in relation to lesional activity and clinical course, with a particular focus on progressive multiple sclerosis. The study is based on detailed quantification of different inflammatory cells in relation to axonal injury in 67 multiple sclerosis autopsies from different disease stages and 28 controls without neurological disease or brain lesions. We found that pronounced inflammation in the brain is not only present in acute and relapsing multiple sclerosis but also in the secondary and primary progressive disease. T- and B-cell infiltrates correlated with the activity of demyelinating lesions, while plasma cell infiltrates were most pronounced in patients with secondary progressive multiple sclerosis (SPMS) and primary progressive multiple sclerosis (PPMS) and even persisted, when T- and B-cell infiltrates declined to levels seen in age matched controls. A highly significant association between inflammation and axonal injury was seen in the global multiple sclerosis population as well as in progressive multiple sclerosis alone. In older patients (median 76 years) with long-disease duration (median 372 months), inflammatory infiltrates declined to levels similar to those found in age-matched controls and the extent of axonal injury, too, was comparable with that in age-matched controls. Ongoing neurodegeneration in these patients, which exceeded the extent found in normal controls, could be attributed to confounding pathologies such as Alzheimer's or vascular disease. Our study suggests a close association between inflammation and neurodegeneration in all lesions and disease stages of multiple sclerosis. It further indicates that the disease processes of multiple sclerosis may die out in aged patients with long-standing disease.

3 August 2015 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
JFJosa M Frischer
Josa M Frischer
SWStephen D. Weigand
Stephen D. Weigand
YGYong Guo
Yong Guo
NKNilufer Kale
Nilufer Kale
JPJoseph E. Parisi
Joseph E. Parisi
CLClaudia F. Lucchinetti
Claudia F. Lucchinetti

20 September 2010 in Brain
Verified
Journal Article
Open access
PDF file
SBStephan Bramow
Stephan Bramow
JFJosa M Frischer
Josa M Frischer
HLHans Lassmann
Hans Lassmann
NKNils Koch-Henriksen
Nils Koch-Henriksen
CLClaudia F. Lucchinetti
Claudia F. Lucchinetti
HLHenning Laursen
Henning Laursen
The causes of incomplete remyelination in progressive multiple sclerosis are unknown, as are the pathological correlates of the different clinical characteristics of patients with primary and secondary progressive disease. We analysed brains and spinal cords from 51 patients with progressive multiple sclerosis by planimetry. Thirteen patients with primary progressive disease were compared with 34 with secondary progressive disease. In patients with secondary progressive multiple sclerosis, we found larger brain plaques, more demyelination in total and higher brain loads of active demyelination compared with patients with primary progressive disease. In addition, the brain density of plaques with high-grade inflammation and active demyelination was highest in secondary progressive multiple sclerosis and remained ∼18% higher than in primary progressive multiple sclerosis after adjustments for other plaque types and plaque number (P < 0.05). Conversely, the proportion of remyelinated shadow plaques (P < 0.05) and the overall remyelination capacity (P < 0.01) per brain were higher in primary, compared with secondary, progressive multiple sclerosis. By contrast, there were no group differences in the brain load or frequency of low-grade inflammatory plaques with slowly expanding demyelination. Spinal cord lesion loads and remyelination capacity were also comparable in the two patient groups. Remyelinated areas were more vulnerable than the normal-appearing white matter to new demyelination, including active demyelination in secondary progressive multiple sclerosis. ‘Recurrent’ slowly expanding demyelination, affecting remyelinated areas, and the load of slowly expanding demyelination correlated with incomplete remyelination in both groups. In turn, incomplete remyelination in the spinal cord correlated with higher disease-related disability (determined retrospectively; r = −0.53; P < 0.05 for remyelination capacity versus disease severity). By contrast, such a correlation was not observed in the brain. We propose that regulatory and reparative properties could protect the white matter of the brain in patients with primary progressive multiple sclerosis. These patients may, thereby, be spared symptoms until the spinal cord is affected. By contrast, recurrent active demyelination of repaired myelin could explain why similar symptoms often develop in consecutive relapses in relapsing-remitting/secondary progressive multiple sclerosis. Our data also indicate that slowly expanding demyelination may irreparably destroy normal and repaired myelin, supporting the concept of slowly expanding demyelination as an important pathological correlate of clinical progression.

1 September 2001 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
PDF file
SBStephan Bramow
Stephan Bramow
POPeter Ott
Peter Ott
FNFinn Thomsen Nielsen
Finn Thomsen Nielsen
KBKristian Bangert
Kristian Bangert
NTNiels Tygstrup
Niels Tygstrup
KDKim Dalhoff
Kim Dalhoff

1 June 2008 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
PDF file
SBS Bramow
S Bramow
JFJc Faber-Rod
Jc Faber-Rod
CJC Jacobsen
C Jacobsen
AKA Kutzelnigg
A Kutzelnigg
PPP Patrikios
P Patrikios
HLH Laursen
H Laursen
We report a case of fatal neurogenic pulmonary edema in progressive multiple sclerosis (MS). The patient had one isolated relapse-like episode. Six years later progressive disease began, lasting 5 years until unexpected death during sleep. Medico-legal autopsy revealed pulmonary edema and neuropathological examination showed infiltrations with lymphocytes and microglia in the respiratory centers of the medulla. More classical demyelinated lesions were found in the white matter of spinal cord and in the gray matter of the brain along with disseminated perivascular lymphocytic infiltrates. Medullary inflammation in progressive MS may result in sudden fatal respiratory failure.

18 May 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
VPViktoria Papp
Viktoria Papp
MBMathias Due Buron
Mathias Due Buron
VSVolkert Siersma
Volkert Siersma
PRPeter Vestergaard Rasmussen
Peter Vestergaard Rasmussen
ZIZsolt Illes
Zsolt Illes
MMMelinda Magyari
Melinda Magyari
Objective: Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) for relapsing forms of multiple sclerosis (MS). We studied clinical outcomes in a real-world setting involving a population-based large cohort of unselected patients enrolled in The Danish Multiple Sclerosis Registry (DMSR) who started teriflunomide treatment between 2013–2019. Methods: This was a complete nationwide population-based cohort study with prospectively enrolled unselected cases. Demographic and disease-specific patient parameters related to treatment history, efficacy outcomes, and discontinuation and switching rates among other clinical variables were assessed at baseline and during follow-up visits. Results: A total of 3239 patients (65.4% female) started treatment with teriflunomide during the study period, 56% of whom were treatment-naïve. Compared to previously treated patients, treatment-naïve patients were older on average at disease onset, had a shorter disease duration, a lower Expanded Disability Status Scale score at teriflunomide treatment start and more frequently experienced a relapse in the 12 months prior to teriflunomide initiation. In the 3001 patients initiating teriflunomide treatment at least 12 months before the cut-off date, 72.7% were still on treatment one year after treatment start. Discontinuations in the first year were due mainly to adverse events (15.6%). Over the full follow-up period, 47.5% of patients discontinued teriflunomide treatment. Sixty-three percent of the patients treated with teriflunomide for 5 years were relapse-free, while significantly more treatment-naïve versus previously treated patients experienced a relapse during the follow-up (p<0.0001). Furthermore, 85% of the patients with available data were free of disability worsening at the end of follow-up. Conclusions: Solid efficacy and treatment persistence data consistent with other real-world studies were obtained over the treatment period. Treatment outcomes in this real-world scenario of the population-based cohort support previous findings that teriflunomide is an effective and generally well-tolerated DMT for relapsing MS patients with mild to moderate disease activity.